Aquestive Therapeutics, Inc. Common Stock (AQST) Stock Price
AQSTStock
$5.02+31.07%52W
Market Cap$630.07M
P/E—
PEG Ratio—
Div yield—
Beta1.51
AQST Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)10.81%
Price vs S&P 500 (4W)30.91%
VGM Score50.58
AQST Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.12 | -$0.07 | +45.67%(+$0.05) | |
| Q1 2026 | -$0.13 | -$0.05 | +64.69%(+$0.08) | |
| Q4 2025 | -$0.12 | -$0.14 | -18.08%(-$0.02) | |
| Q3 2025 | -$0.13 | -$0.14 | -5.66%(-$0.01) | |
| Q2 2025 | -$0.17 | -$0.12 | +32.27%(+$0.06) |
AQST Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.20
4.20
4.20
4.20
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AQSTAquestive Therapeutics, Inc. Common Stock | D | C | B | $5.02 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Aquestive Therapeutics, Inc. Common Stock
Aquestive Therapeutics is a specialty pharmaceutical company developing and commercializing products for central nervous system disorders and severe allergic reactions. The company markets four commercial products—Suboxone, Emylif, Ondif, and Sympazan—with pipeline candidates including Libervant Buccal Film and AQST-108. Revenue is primarily generated in the United States.